Refine by
Micoryx Tumor Response Equipment & Supplies
1 equipment items found
Manufactured by:ORYX GmbH & Co. KG based inBaldham, GERMANY
These mutations lead to the inactivation of specific proteins and to the expression of frameshift peptides (FSPs). These FSPs are tumor-specific antigens, which are constantly expressed. Cancers with MSI-H mutations include 10-15 % of colorectal cancers, 20-25 % of endometrial cancers, 25-30 % of upper urinary tract cancers, 15-20 % of intestinal gastric cancers and 5-10% of ...